Zacks Small Cap Has Optimistic View of MIRA FY2026 Earnings

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) – Zacks Small Cap increased their FY2026 earnings per share estimates for MIRA Pharmaceuticals in a report released on Tuesday, April 1st. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings of ($0.53) per share for the year, up from their prior forecast of ($0.54). The consensus estimate for MIRA Pharmaceuticals’ current full-year earnings is ($0.60) per share.

MIRA Pharmaceuticals (NASDAQ:MIRA) last released its earnings results on Friday, March 28th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.14.

MIRA Pharmaceuticals Stock Performance

NASDAQ:MIRA opened at $0.95 on Thursday. The firm’s 50-day moving average is $1.11 and its 200-day moving average is $1.22. The company has a market cap of $15.70 million, a price-to-earnings ratio of -1.69 and a beta of 2.31. MIRA Pharmaceuticals has a 52-week low of $0.51 and a 52-week high of $5.01.

Hedge Funds Weigh In On MIRA Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MIRA. Two Sigma Investments LP bought a new position in MIRA Pharmaceuticals in the fourth quarter worth $28,000. International Assets Investment Management LLC acquired a new position in shares of MIRA Pharmaceuticals in the 4th quarter valued at $29,000. Northern Trust Corp lifted its holdings in shares of MIRA Pharmaceuticals by 50.9% during the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock worth $35,000 after acquiring an additional 10,238 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of MIRA Pharmaceuticals during the 4th quarter valued at about $52,000. Finally, Virtu Financial LLC bought a new stake in MIRA Pharmaceuticals in the fourth quarter valued at about $72,000. 35.16% of the stock is currently owned by institutional investors.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.